FREE

MOSL: HEALTHCARE- IPM – growth continues to recover on higher volumes

HEALTHCARE: IPM – growth continues to recover on higher volumes

 

• Indian pharmaceutical market's (IPM) secondary sales continued to grow at a healthy rate in January, led by strong volume growth, though price growth continued to drag. IPM grew 9.5% YoY in January 2018 and 8.3% YoY over November-January 2018.
• Volume growth has been increasing for the last two quarters, after declining in the April-July 2017 quarter. In January 2018, volume growth was 6.7% YoY. Growth in new products has remained stable in the last 3-4 quarters (up 2.9% YoY in January). Prices continued to decline for the second quarter. In January 2018, the price decline was 1.4% YoY.
• Moving annual total (MAT) growth for January was 5.6% YoY against 5.5% YoY in December. 

 

Lupin, Mankind and Alkem witness highest growth

• Lupin’s secondary sales (+16.5%) posted robust growth for January, followed by Mankind (+16.4%), Alkem (+13.5%), Sun Pharma (+12%), Abbott India (+10.6%), Glenmark (+12.6%), and Sanofi India (+12.8%), which registered growth higher than IPM.
• Over 60% of the companies posted high-single-digit to mid-double-digit growth during the month.

 Respiratory, Vaccines and Hormones lead among therapies

• Respiratory (7.5% of IPM) posted significant growth of 19.3% YoY in January, followed by Vaccines (+15.9%; 1.9% of IPM) and Hormones (+15.1%; 1.7% of IPM). Except for Anti-Neoplastics (2.1% of IPM), which remained muted for the month, all therapies reported growth in January.
• 50% of the therapies reported growth higher than IPM during the month.